radiotherapy and sarcomas
TRANSCRIPT
![Page 1: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/1.jpg)
Radiotherapy and Sarcomas
Wendy Ella
University College London Hospitals
NHS Foundation Trust
![Page 2: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/2.jpg)
Introduction
• Rare malignant tumours arising from mesenchymal tissue
• <1% malignant tumours
• 78% originate from soft tissue, remainder from bone
• Diverse group
![Page 3: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/3.jpg)
Heterogenous group of tumours
• Malignant Fibrous histiocytoma 28%• Liposarcoma 15%• Leiomyosarcoma 12%• Synovial sarcoma 10%• MPNST 5%• Rhabdomyosarcoma 5%• Fibrosarcoma <5• Ewings sarcoma • Angiosarcoma• Osteosarcoma• Clear cell sarcoma• Alveolar soft part sarcoma• Hamangiopericytoma• Chondrosarcoma
![Page 4: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/4.jpg)
Introduction
• Increasing frequency with age
• Most commonly arising in the limbs– Extremities 50%– Trunk and retroperitoneal space 40%– Head and neck region 10%
![Page 5: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/5.jpg)
Heterogenous group of tumours
![Page 6: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/6.jpg)
Heterogenous group of tumours
![Page 7: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/7.jpg)
Heterogenous group of tumours
![Page 8: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/8.jpg)
Heterogenous group of tumours
![Page 9: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/9.jpg)
Principles of management: soft tissue sarcomas
Surgery
+/- Radiotherapy
+/- Chemotherapy
![Page 10: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/10.jpg)
Radiotherapy for soft tissue sarcoma
• Radiotherapy – role optimise local control
• Local control rates for combination of surgery + radiotherapy similar to amputation without affecting patient survival (Potter et al; 1986).
• Yang et al, J Clin Oncol, 1998, looked at high grade extremity lesions: Surgery vs Surgery + EBRT (63Gy in 1.8Gy), - increased local control from 70% to 99%, No difference in OS.
• Summary: Post operative radiotherapy is highly effective in preventing local recurrence.
![Page 11: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/11.jpg)
Pre- or Post-Op Radiotherapy?
O’Sullivan et al; Five year results of randomised phase III trial of pre-op vs. post-op radiotherapy in extremity STS; JCO 2004 190 patients (94 pre-op/96 post-op) 5 year local control 93% v 92%, metastatic relapse free 67% v 69%, recurrence free survival; 58% v 59%, overall survival 73% v 67%
• Pre-op and post-op radiotherapy equally effective, normal tissue complication rate varies for both - therefore need to take in to account anatomical site
![Page 12: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/12.jpg)
Indications for Post Operative Radiotherapy;
• Consider for all high grade sarcomas.
• Consider for low-intermediate grade with marginal excision/positive margins if further surgery not possible
• Following removal of recurrent tumour
![Page 13: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/13.jpg)
Indications for pre-operative radiotherapy
• If tumour adjacent to or involving critical structures.
• Likely difficult resection.
• Tumour initially inoperable at diagnosis
![Page 14: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/14.jpg)
Planning post-operative radiotherapy
• Immobilisation
• Definition of target volume
• Phase I & II
• Field arrangements
• Implementation of plan
![Page 15: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/15.jpg)
Immobilisation
• Impression of limb with patient in the optimum treatment position -sheet of thermoplastic (Orfit) moulded around limb – clipped onto baseboard
• Immobilise limb• Same position every day• Reduce marks being drawn on skin
![Page 16: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/16.jpg)
Immobilisation: Lower limb
![Page 17: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/17.jpg)
Immobilisation: Upper limb
![Page 18: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/18.jpg)
Phase I Volume definition
• GTV reconstructed from pre-op imaging.• Consider compartment at risk of microscopic spread.
Should include biopsy site and scar
CTV (length) = GTV + 4-9cm (usually ~5cm)PTV = CTV + 5-10mm (depending on departmental set up) or 1 cm beyond scar
Trans-axial CTV - treat width of compartment or GTV + 2-3cm
![Page 19: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/19.jpg)
Phase II Volume definition
• Length
PTV = GTV +2-3cm
• Width
PTV is usually the same as phase I in axial plane
![Page 20: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/20.jpg)
Sparing a “corridor”
• Leaving an area of normal tissue within the circumference of the limb can reduce risk of lymphoedema
![Page 21: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/21.jpg)
Vortex
• CTV1 = axial 2cm or fascia• Longitudinal 2cm
• CTV2 = axial 2cm or fascia• Longitudinally 2cm
• CTV- PTV = 5mm
![Page 22: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/22.jpg)
![Page 23: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/23.jpg)
![Page 24: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/24.jpg)
![Page 25: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/25.jpg)
Margin calculation
• Van Herk, Seminars in Radiation Oncology, 14, 2004, 52-64
• Margin = (2.5 X SD of group systematic error) + (0.7 X SD of random error)
![Page 26: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/26.jpg)
Systematic/Random errors
Group systematic
error
Group SD of random error
Margins calculated
L-R on AP
0.2 mm
+/- 1.4 SD
+/- 1.1mm 4.3 mm
S-I on AP
-0.2 mm
+/- 1.7 SD
+/- 1.7mm 5.3 mm
A–P on Lat
0.3 mm
+/- 1.5 SD
+/- 0.8mm 4.4 mm
Margin = (2.5 X SD of group systematic error) + (0.7 X SD of random error) - Van Herk, 2004
![Page 27: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/27.jpg)
Implementation of Plan
• 6MV photons• Prescribed to 100%• Given isocentrically treating all fields daily• Limbs 2 phase technique;
phase I 50Gy in 25# over 5 weeksphase II 10 -16Gy in 5# over 1 week
• 60Gy is standard post op dose, 66Gy if positive margin
![Page 28: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/28.jpg)
MRI Scan
![Page 29: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/29.jpg)
Planning
![Page 30: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/30.jpg)
Planning
![Page 31: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/31.jpg)
Radiotherapy for soft tissue sarcoma
• Complex radiotherapy
• Highly individualised
• Requires good anatomical knowledge
![Page 32: Radiotherapy And Sarcomas](https://reader036.vdocument.in/reader036/viewer/2022062405/556af66bd8b42a2a4f8b482d/html5/thumbnails/32.jpg)
Questions?
University College London Hospitals
NHS Foundation Trust